Pharma Mar (OTCMKTS:PHMMF) Shares Gap Down – Time to Sell?

Pharma Mar (OTCMKTS:PHMMF)’s share price gapped down prior to trading on Friday . The stock had previously closed at $94.3374, but opened at $90.90. Pharma Mar shares last traded at $90.90, with a volume of 102 shares changing hands.

Analyst Ratings Changes

A number of equities research analysts have commented on PHMMF shares. Chardan Capital raised shares of Pharma Mar to a “strong-buy” rating in a report on Tuesday, June 9th. Zacks Research upgraded shares of Pharma Mar to a “hold” rating in a research report on Monday, June 15th. Finally, BTIG Research initiated coverage on shares of Pharma Mar in a research note on Thursday, April 23rd. They set a “buy” rating on the stock. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.

Pharma Mar Stock Down 3.6%

The company has a debt-to-equity ratio of 0.14, a current ratio of 3.02 and a quick ratio of 2.44. The company has a 50 day moving average price of $96.28 and a 200 day moving average price of $93.84.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.